Kardigan, Inc.

What they do

Kardigan develops three late-stage drug candidates targeting root causes of cardiovascular disease. Its pipeline includes danicamtiv, a myosin activator for genetic dilated cardiomyopathy; ataciguat, an sGC activator for calcific aortic valve stenosis; and tonlamarsen, an antisense oligonucleotide for acute severe hypertension. The company is headquartered in Princeton, NJ, and is supported by its Prolaio platform.

Revenue drivers

• Danicamtiv — Myosin activator in a Phase 2b/3 adaptive trial (KINSHIP-DCM) for genetic DCM; Phase 2b topline data expected 1H 2027.
• Ataciguat — sGC activator in Phase 2b (KATALYST-AV) for calcific aortic valve stenosis; interim 24-week topline data expected 1H 2027.
• Tonlamarsen — Antisense oligonucleotide in Phase 2 (KARDINAL-ASH) for acute severe hypertension; first patient randomized in Q2 2026, topline data expected 1H 2027.

Recent performance

As of June 30, 2026, Kardigan reported total assets of $721.8 million, total liabilities of $106.3 million, and shareholder equity of $615.5 million. Cash, cash equivalents, and investments were $660.7 million, up from $335.5 million at December 31, 2025, primarily due to net proceeds from the June 2026 IPO. The company completed enrollment of Cohort 1 in the Phase 2b KINSHIP-DCM trial and began Phase 3 enrollment. It also randomized the first patient in the Phase 2 KARDINAL-ASH trial.

Strategy

Kardigan is advancing three late-stage cardiovascular programs through clinical data readouts and into Phase 3 trials. The company raised $460 million in gross proceeds from its June 2026 IPO to fund these efforts. Management expects multiple clinical milestones over the next 12 months that will shape the registrational path for each medicine. The Prolaio platform supports the development of these precision therapeutics.

Risks

• Clinical trial failure — All three programs are in clinical development and could fail to show safety or efficacy, delaying or preventing regulatory approval.
• No approved products — Kardigan has no approved products and has not generated product revenue, relying on financing to fund operations.
• Regulatory uncertainty — The FDA or other regulators may not accept the company's trial designs or may require additional studies, increasing costs and timelines.
• Competition — Other companies are developing treatments for cardiovascular diseases, which could reduce Kardigan's potential market share.

Outlook

Management expects Phase 2b topline data for danicamtiv and ataciguat, and Phase 2 topline data for tonlamarsen, in the first half of 2027. The company's current cash runway is expected to support advancement of all three programs through these readouts and the initiation of Phase 3 trials. Additional data will be presented at the European Society of Cardiology Congress in August 2026.